asymmetric dimethylarginin (adma) as a marker of endothelial dysfunction in primary aldosteronism

نویسندگان

joanna matrozova clinical centre of endocrinology, medical university-sofia, zdrave 2 st, sofia, bulgaria

vladimir vasilev clinical centre of endocrinology, medical university-sofia, zdrave 2 st, sofia, bulgaria

silvia vandeva clinical centre of endocrinology, medical university-sofia, zdrave 2 st, sofia, bulgaria

atanaska elenkova clinical centre of endocrinology, medical university-sofia, zdrave 2 st, sofia, bulgaria

چکیده

conclusions the lack of difference between adma levels in patients with pa and eh suggests that endothelial dysfunction is more likely related to hypertension per se than to the specific etiology of elevated blood pressure. results patients with pa had significantly higher concentrations of adma than healthy controls (0.488 ± 0.085 vs. 0.433 ± 0.053 μmol/l, p = 0.027). no difference was found in adma levels between cases with pa and eh (0.488 ± 0.085 vs. 0.476 ± 0.075 μmol/l, р = 0.636). the difference between patients with eh and normotensive controls did not reach statistical significance (p = 0.06). background recent studies have revealed a higher rate of cardiovascular complications in primary aldosteronism (pa) compared to patients with essential hypertension (eh). asymmetric dimethylarginine (adma) is a marker of endothelial dysfunction that could contribute to increased cardiovascular risk in patients with pa. objectives the aim of this study was to compare the levels of adma among patients with pa, controls with eh and healthy participants. methods: serum adma levels were determined, using commercially available competitive enzyme-linked immunosorbent assay. methods serum adma levels were determined, using commercially available competitive enzyme-linked immunosorbent assay.

برای دانلود باید عضویت طلایی داشته باشید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Asymmetric Dimethylarginin (ADMA) as a Marker of Endothelial Dysfunction in Primary Aldosteronism

BACKGROUND Recent studies have revealed a higher rate of cardiovascular complications in primary aldosteronism (PA) compared to patients with essential hypertension (EH). Asymmetric dimethylarginine (ADMA) is a marker of endothelial dysfunction that could contribute to increased cardiovascular risk in patients with PA. OBJECTIVES The aim of this study was to compare the levels of ADMA among p...

متن کامل

Asymmetric Dimethylarginine (ADMA) and Endothelial Dysfunction: Implications for Atherogenesis

Atherosclerotic coronary heart disease is the leading cause of morbidity and mortality in industrialized countries, and endothelial dysfunction is considered a precursor phenomenon. The nitric oxide produced by the endothelium under the action of endothelial nitric oxide synthase has important antiatherogenic functions. Its reduced bioavailabilty is the beginning of the atherosclerotic process....

متن کامل

Does ADMA cause endothelial dysfunction?

Asymmetric dimethylarginine (ADMA) is an endogenous and competitive inhibitor of nitric oxide synthase. Plasma levels of this inhibitor are elevated in patients with atherosclerosis and in those with risk factors for atherosclerosis. In these patients, plasma ADMA levels are correlated with the severity of endothelial dysfunction and atherosclerosis. By inhibiting the production of nitric oxide...

متن کامل

Role in Hypercholesterolemia Asymmetric Dimethylarginine (ADMA): A Novel Risk Factor for Endothelial Dysfunction

Rainer H. Böger, Stefanie M. Bode-Böger, Andrzej Szuba, Philip S. Tsao, Jason R. Chan, : Its Role in Hypercholesterolemia Asymmetric Dimethylarginine (ADMA): A Novel Risk Factor for Endothelial Dysfunction Print ISSN: 0009-7322. Online ISSN: 1524-4539 Copyright © 1998 American Heart Association, Inc. All rights reserved. is published by the American Heart Association, 7272 Greenville Avenue, Da...

متن کامل

Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia.

BACKGROUND Asymmetric dimethylarginine (ADMA) is an endogenous competitive inhibitor of nitric oxide (NO) synthase. Because endothelial NO elaboration is impaired in hypercholesterolemia, we investigated whether plasma concentrations of ADMA are elevated in young, clinically asymptomatic hypercholesterolemic adults. We further studied whether such elevation of ADMA levels was correlated with im...

متن کامل

Metabolic dysfunction in primary aldosteronism.

Metabolic Dysfunction in Primary Aldosteronism To the Editor: The study by Matrozova et al1 analyzed retrospectively the metabolic parameters of a large French cohort of patients with primary aldosteronism (PA) who were compared with matched patients with primary hypertension (PH). In these 2 groups of patients, fasting plasma glucose levels, as well as the prevalence of hyperglycemia, were com...

متن کامل

منابع من

با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید


عنوان ژورنال:
international journal of endocrinology and metabolism

جلد ۱۴، شماره ۴، صفحات ۰-۰

میزبانی شده توسط پلتفرم ابری doprax.com

copyright © 2015-2023